Physician profile
Jill E Mackey
NPI 1578505863
$20,438.51
in general payments reported to CMS, 2019-2025
49 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,870 · 2020: $3,828 · 2021: $3,182 · 2022: $2,019 · 2023: $2,040 · 2024: $2,817 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,040 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,039.61 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $5,150.00 | 2019-2025 | |
| Novo Nordisk INC | $2,243.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,845.26 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,494.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,434.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,427.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $1,054.24 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $873.82 | 2019-2025 | Jardiance |
| Pfizer INC. | $780.52 | 2019-2025 | |
| Astellas Pharma US INC | $774.99 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $489.14 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $277.60 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $267.59 | 2023-2025 | Quviviq, Quviviq |
| Amgen INC. | $243.84 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $205.23 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.